Treatments that suppress or alter immune system activity may help some children and adolescents with juvenile myasthenia gravis (JMG), but more studies are needed to help define the potential benefits and determine best practices. That’s according to a meta-analysis of published studies reporting outcomes of JMG patients who were…
News
June is Myasthenia Gravis Awareness Month, and advocates around the world are planning a range of events to raise awareness of myasthenia gravis (MG). “MG community members, including patients, care partners, and healthcare providers, host advocacy activities in June each year to promote a broader global understanding of the…
Treatment with Vyvgart (efgartigimod) was associated with rapid and sustained symptom easing, lower corticosteroid use, and no unexpected safety concerns in a small real-world study of adults with generalized myasthenia gravis (gMG). The findings suggest the therapy may be a useful option in individualized treatment plans, although larger,…
Top-line results from a global, late-stage clinical trial testing the experimental cell therapy Descartes-08 against a placebo in adults with generalized myasthenia gravis (gMG) are expected in the first months of 2027. The Phase 3 study, AURORA (NCT06799247), aims to enroll about 100 adults with gMG who test…
More than half of myasthenia gravis (MG) patients with bulbar symptoms, or difficulties swallowing, chewing, and/or speaking, experience a disease exacerbation shortly after starting corticosteroid treatment, according to a study in China. The risk for early exacerbation, or sudden symptom worsening, was found to be significantly higher among patients…
People with myasthenia gravis (MG) tend to have fewer hospitalizations and less need for corticosteroids after starting treatment with Rystiggo (rozanolixizumab-noli), according to an analysis of insurance claims data from the U.S. Corticosteroids are anti-inflammatory medications commonly used in MG, “but long-term use is associated with a…
An eyedrop formulation of neostigmine, an acetylcholinesterase inhibitor (AChEI) whose oral formulation was once a mainstay treatment for myasthenia gravis (MG), may safely reduce drooping eyelids in people with the neuromuscular disease. That’s according to data from a small Phase 1 clinical trial (ACTRN12624000545561), which showed that one…
Being pregnant does not increase the risk of hospitalizations for women with myasthenia gravis (MG), a study in Sweden found. Findings also indicate that the risk of MG-related hospitalization is not significantly increased after birth. However, for the minority of patients who are hospitalized during this period, these hospitalizations…
A high-fat, low-carbohydrate ketogenic diet may significantly reduce muscle weakness and fatigue for people living with generalized myasthenia gravis (gMG), according to a new pilot clinical trial. Patients who followed the “keto” regimen for 12 weeks saw clinically meaningful improvements in their physical symptoms compared to those who stuck…
The Myasthenia Gravis Foundation of America (MGFA) awarded four grants, each valued at $110,000, to research projects aimed at better understanding the biology of myasthenia gravis (MG) and improving its diagnosis and treatment. “MGFA is helping to fuel a sea change in myasthenia gravis diagnosis and care,” Samantha…
Recent Posts
- I’m just beginning the journey of living with myasthenia gravis
- What I wish people understood when they say, ‘Must be nice’
- Moving forward together: Living with MG means accepting the realities
- I wanted to believe my twin had learned to make peace with MG
- Restarting a favorite physical activity after MG diagnosis has helped me heal